Should I buy or sell Galectin Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GALT shares. View GALT analyst ratings or view top-rated stocks .

What is Galectin Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued twelve-month price objectives for Galectin Therapeutics' stock. Their GALT share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 226.4% from the stock's current price. View analysts price targets for GALT or view top-rated stocks among Wall Street analysts .

How have GALT shares performed in 2024?

Galectin Therapeutics' stock was trading at $1.66 at the beginning of the year. Since then, GALT shares have increased by 103.0% and is now trading at $3.37. View the best growth stocks for 2024 here .

Are investors shorting Galectin Therapeutics?

Galectin Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,250,000 shares, an increase of 5.1% from the March 15th total of 2,140,000 shares. Based on an average daily volume of 105,800 shares, the short-interest ratio is presently 21.3 days. Currently, 5.3% of the company's stock are short sold. View Galectin Therapeutics' Short Interest .

When is Galectin Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our GALT earnings forecast .

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) announced its earnings results on Monday, November, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04.

What ETF holds Galectin Therapeutics' stock?

Horizon Kinetics Medical ETF holds 53,742 shares of GALT stock, representing 1.17% of its portfolio.

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE) , Catalyst Pharmaceuticals (CPRX) , Viking Therapeutics (VKTX) , Exelixis (EXEL) , Progenics Pharmaceuticals (PGNX) , Rigel Pharmaceuticals (RIGL) , TherapeuticsMD (TXMD) , Novavax (NVAX) , Verastem (VSTM) and Immunomedics (IMMU) .

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Retirement Guys Formula LLC (0.05%). Insiders that own company stock include Elissa J Schwartz , Fund LP 10X, Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard A Jr Zordani . View institutional ownership trends .

How do I buy shares of Galectin Therapeutics?

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GALT

Galectin Therapeutics (GALT) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free GALT Stock Alerts

$3.37

-0.01 (-0.30%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.20
▼
$3.47
50-Day Range: $1.66
▼
$4.20
52-Week Range: $1.28
▼
$4.27

Volume: 206,132 shs
Average Volume: 275,773 shs
Market Capitalization: $208.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get Galectin Therapeutics alerts:

Galectin Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 226.4% Upside
$11.00 Price Target
Short Interest: Bearish
5.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.48
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.66) to ($1.59) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.07 out of 5 stars

Medical Sector

776th out of 911 stocks

Pharmaceutical Preparations Industry

344th out of 409 stocks

3.5

Analyst's Opinion

Consensus Rating
Galectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Galectin Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
5.31% of the float of Galectin Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Galectin Therapeutics has a short interest ratio ("days to cover") of 21.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Galectin Therapeutics has recently increased by 5.14%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Galectin Therapeutics does not currently pay a dividend.
Dividend Growth
Galectin Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GALT.

3.0

News and Social Media Coverage

News Sentiment
Galectin Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Galectin Therapeutics this week, compared to 1 article on an average week.
Search Interest
9 people have searched for GALT on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
MarketBeat Follows
8 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Galectin Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
52.70% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.68% of the stock of Galectin Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.66) to ($1.59) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Galectin Therapeutics is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Galectin Therapeutics is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Galectin Therapeutics Stock (NASDAQ:GALT)

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

GALT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GALT Stock News Headlines

April 20, 2024 | morningstar.com

Galectin Therapeutics Inc GALT

April 18, 2024 | americanbankingnews.com

Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Update

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 12, 2024 | americanbankingnews.com

Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT)

April 10, 2024 | americanbankingnews.com

Galectin Therapeutics (NASDAQ:GALT) Given Buy Rating at HC Wainwright

April 9, 2024 | markets.businessinsider.com

Galectin Therapeutics Gets DSMB's Nod To Continue Phase 2b/3 NAVIGATE Study Of Belapectin

April 9, 2024 | finance.yahoo.com

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis

April 5, 2024 | investorplace.com

GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 3, 2024 | benzinga.com

Galectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, Predictions

April 2, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Galectin Therapeutics Amidst Positive Clinical Trial Progress and Enhanced Financial Stability

March 29, 2024 | finanznachrichten.de

Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

March 29, 2024 | msn.com

What retail stores are open Easter 2024? Details on Walmart, Target, Macy's, Kohl's, more

March 29, 2024 | finance.yahoo.com

Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments

March 29, 2024 | globenewswire.com

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

March 20, 2024 | seekingalpha.com

Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point

March 14, 2024 | msn.com

Madrigal granted FDA approval for NASH therapy

March 13, 2024 | msn.com

Liver drug developers outperform as U.S. awaits first NASH drug

March 12, 2024 | globenewswire.com

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

February 29, 2024 | seekingalpha.com

GALT Galectin Therapeutics Inc.

February 21, 2024 | finance.yahoo.com

Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%

November 14, 2023 | markets.businessinsider.com

Arce’s Buy Rating on Galectin Therapeutics: Promising NAVIGATE Trial Progress and Strong Financial Outlook

November 13, 2023 | msn.com

Galectin Therapeutics GAAP EPS of -$0.24

November 13, 2023 | benzinga.com

Galectin Therapeutics: Q3 Earnings Insights

November 13, 2023 | finance.yahoo.com

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

November 13, 2023 | finance.yahoo.com

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

November 13, 2023 | finance.yahoo.com

Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023

See More Headlines

Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GALT
CUSIP: N/A
CIK: 1133416
Web: www.galectintherapeutics.com
Phone: (678) 620-3186
Fax: 770-864-1327
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +226.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.74)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,070,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -197.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.77
Quick Ratio: 1.77

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.01) per share
Price / Book: -3.34

Miscellaneous

Outstanding Shares: 61,904,000
Free Float: 29,281,000
Market Cap: $208.62 million
Optionable: Optionable
Beta: 0.84

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Joel Lewis (Age 54)
President, CEO & Director
Comp: $907.72k
Mr. Jack W. Callicutt CPA (Age 57)
CFO, Treasurer & Corporate Secretary
Comp: $521.47k
Dr. Pol F. Boudes M.D. (Age 67)
Ph.D., Chief Medical Officer
Comp: $730.33k
Robert Tritt
General Counsel
Mr. Jeff Katstra
Head of CMC & Pharmaceutical Development
Ms. Beth Knowles
Executive Assistant & Officer Manager

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Galectin Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GALT shares.
View GALT analyst ratings or view top-rated stocks.
What is Galectin Therapeutics' stock price target for 2024?: 1 Wall Street analysts have issued twelve-month price objectives for Galectin Therapeutics' stock. Their GALT share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 226.4% from the stock's current price.
View analysts price targets for GALT or view top-rated stocks among Wall Street analysts.
How have GALT shares performed in 2024?: Galectin Therapeutics' stock was trading at $1.66 at the beginning of the year. Since then, GALT shares have increased by 103.0% and is now trading at $3.37.
View the best growth stocks for 2024 here.
Are investors shorting Galectin Therapeutics?: Galectin Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,250,000 shares, an increase of 5.1% from the March 15th total of 2,140,000 shares. Based on an average daily volume of 105,800 shares, the short-interest ratio is presently 21.3 days. Currently, 5.3% of the company's stock are short sold.
View Galectin Therapeutics' Short Interest.
When is Galectin Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our GALT earnings forecast.
How were Galectin Therapeutics' earnings last quarter?: Galectin Therapeutics Inc. (NASDAQ:GALT) announced its earnings results on Monday, November, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04.

What ETF holds Galectin Therapeutics' stock?: Horizon Kinetics Medical ETF holds 53,742 shares of GALT stock, representing 1.17% of its portfolio.
What other stocks do shareholders of Galectin Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).
Who are Galectin Therapeutics' major shareholders?: Galectin Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Retirement Guys Formula LLC (0.05%). Insiders that own company stock include Elissa J Schwartz, Fund LP 10X, Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard A Jr Zordani.
View institutional ownership trends.
How do I buy shares of Galectin Therapeutics?: Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GALT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Galectin Therapeutics (GALT) Stock Price, News & Analysis

Galectin Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Galectin Therapeutics Stock (NASDAQ:GALT)

GALT Stock Price History

GALT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GALT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™